Severe Asthma Study QAW039
Do you have severe, uncontrolled asthma and are you taking medication to treat your asthma? If so, you may be able to take part in a research study to find out if an investigational study drug called QAW039 can reduce the number of asthma attacks you have and make your asthma symptoms better. Compensation provided.

Study Purpose
Severe asthma, which affects approximately 5%-10% of asthmatics, is difficult to treat. The purpose of this study is to see if adding the investigational study drug QAW039 to your usual asthma medicines can reduce the number of asthma attacks you have, make asthma symptoms better, and improve your quality of life. Researchers also want to find out if you have any side effects when you are taking the study drug.

QAW039 is an investigational drug which has not been approved for sale in the United States by the U.S. Food and Drug Administration (FDA) for the treatment of people with asthma. QAW039 has been tested in studies with healthy people who do not have disease and in people with a variety of different diseases.

QAW039 works by blocking a receptor called CRTh2. When this receptor is blocked, blood cells (such as eosinophils) that cause inflammation are prevented from moving into the lungs. If blood cells such as eosinophils move to your lungs and cause inflammation, your airway can become more narrow or restricted, and asthma symptoms like wheezing and shortness of breath can occur.

Could This Study Be Right for You?
- Ages 18 and up
- Have severe, uncontrolled asthma
- Diagnosed with asthma for at least two years
- Taking medication for asthma
- Had two or more asthma attacks within the past year that required treatment with systemic corticosteroids (prednisone, prednisolone, methylprednisolone, beclomethasone, betamethasone, dexamethasone, hydrocortisone, triamcinolone) OR that required you to be hospitalized for at least 24 hours
- Non-smoker or tobacco-free for at least six months

What Participants Can Expect
Participation involves 11 study visits and 6 phone calls over 14 months. Study visits will take anywhere from 1-4 hours to
It is important to know that some patients on this study will receive QAW039 and some will receive a placebo. The placebo looks and tastes just like QAW039 but does not contain any QAW039. You will be assigned by chance, like the flip of a coin, to receive either QAW039 or placebo. All participants will be asked to take their usual study medication for this entire time.

**IRB:** Quorum# 31020/23A  A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma

**MEET THE RESEARCHER**

Sally E. Wenzel, MD, has a passion for understanding and improving the treatment of asthma, particularly severe asthma. She served as Chair of the ATS workshop on severe asthma that developed the international consensus definition of severe asthma. Dr. Wenzel has been listed as one of Castle Connelly’s top doctors in America for over 10 years.